Therma Bright Inc V.THRM

Alternate Symbol(s): TBRIF

Technology Scientific & Technical Instruments

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.

TSXV:THRM - Post by User

Therma Bright Inc > Remember this press release

<< Previous

Bullboard Posts

Next >>

Comment by Moemoney42on Nov 17, 2021 2:26pm

118 Views

Post# 34137396

RE:RE:Remember this press release

LMAO... ya LAC shorting cost you what.. $40G of lost money... LOL... those $29.32's and $33.90's are still losing shorts.. that you probably covered when LAC spiked to $45 bucks.. LMAO the truth hurts eh.. LOL..

Kaiser wrote:
the troll returns. Have balls and short it or return to pumping Sona. Lol!

btw. Lac shorting has been ridiculous. Ouuuuuch! The pump is over. Dump time.

Moemoney42 wrote: "Toronto, Ontario–(Newsfile Corp. – December 7, 2020) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), a progressive medical device technology company, is pleased to announce the preliminary results achieved during the feasibility studies indicate a test sensitivity of 80% and a specificity of over 90% for Therma’s CoviSafe™ rapid test for detecting SARS-CoV-2 in saliva
Testing is expected to start before year end, but because of potential delays due to the holidays, may extend into January.
Once testing is complete and a minimum set with 300 samples data will be compiled and sent to both FDA and Health Canada for approval under EUA with FDA and the Interim Order with Health Canada. The Company expects to submit data to both regulatory agencies in early 2021"

So looks like they missed their own self emposed deadlines by a year.. as of this Dec. they might be done field testing for FDA approval.. then maybe the FDA will look at it in the new year if the field data can be replicated.. then on to HC.. more wait time.. no wonder the stock has languished all year.. :-(